Olanzapine Actavis

Phase 3Small molecule

TTan Tock Seng Hospital

Olanzapine Actavis is one of 28 small molecule programs targeting Delirium. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

DeliriumActive, not recruiting

DeliriumPhase 3

Active, not recruiting

Competition

Competitive Landscape

167 competitors in Delirium

#DrugCompanyPhaseTrials

Provigil

NNuvo Research GmbH

Phase 3

1 2

Lidocaine IV

KKasr El Aini Hospital

Phase 3

1 3

Physostigmine

AstraZeneca

Phase 3

1 4

Rozerem

Takeda

Preclinical

6 5

Olanzapine Actavis

TTan Tock Seng Hospital

Phase 3

1 6

Inapsine

Alnylam Pharmaceuticals

Preclinical

1 7

Anerem

AAcacia Pharma Ltd

Preclinical

7 8

Spravato

WWim Janssens

Preclinical

4 9

Raldesy

PPragma

Preclinical

3 10

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Delirium1 trial

HALO Trial: Haloperidol vs Olanzapine in Hyperactive Delirium in Palliative Care Patients; A Multi-Centre, Randomised-Controlled Trial

Recruiting·TTan Tock Seng Hospital·Phase 3·NCT04833023·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Olanzapine Actavis. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Olanzapine Actavis compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Olanzapine Actavis. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tan Tock Seng Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: TTan Tock Seng Hospital

Olanzapine Actavis

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Delirium1 trial

References

Drug Info

Quick Facts

Related News